This opportunity targets a multi-billion-dollar gap in research histopathology, where analog processes still dominate. Histowitz offers an end-to-end tech-enabled pathology platform, reducing turnaround times from 1–2 months to just 3 days. With a profitable core business and 30% CAGR since 2019, the company is now monetizing its digital platform and entering its next phase of scalable growth.
Over 3,000 researchers from 500+ organizations—including Harvard, Stanford, Johns Hopkins, Memorial Sloan Kettering, and Bristol Myers Squibb—rely on Histowitz for critical histology and data infrastructure. With more than 600,000 slides hosted, the platform supports AI-powered image analysis, remote pathology consults, and fully digitized data workflows.
With an estimated $48B+ total addressable market and less than 5% digitization penetration, the upside is significant. The team, drawn from top-tier clinical, technical, and diagnostic institutions, is executing a proven scale strategy. A $5M convertible note is now open to accelerate platform growth ahead of a planned Series B in Q4 2025.
View the deck through the link below. Some unique identifiers have been removed. For access to detailed materials, please reach to us or your point of contact, as full decks are only shared upon request to maintain confidentiality and exclusivity.
View Pitch Deck